A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection.

نویسندگان

  • Robert W Hepler
  • Rosemarie Kelly
  • Tessie B McNeely
  • Hongxia Fan
  • Maria C Losada
  • Hugh A George
  • Andrea Woods
  • Leslie D Cope
  • Alka Bansal
  • James C Cook
  • Gina Zang
  • Steven L Cohen
  • Xiaorong Wei
  • Paul M Keller
  • Elizabeth Leffel
  • Joseph G Joyce
  • Louise Pitt
  • Loren D Schultz
  • Kathrin U Jansen
  • Myra Kurtz
چکیده

Infection by Bacillus anthracis is preventable by prophylactic vaccination with several naturally derived and recombinant vaccine preparations. Existing data suggests that protection is mediated by antibodies directed against the protective antigen (PA) component of the anthrax toxin complex. PA is an 83-kDa protein cleaved in vivo to yield a biologically active 63-kDa protein. In an effort to evaluate the potential of yeast as an expression system for the production of recombinant PA, and to determine if the yeast-purified rPA63 can protect from a lethal inhalational challenge, the sequence of the 63-kDa form of PA was codon-optimized and expressed in the yeast Saccharomyces cerevisiae. Highly purified rPA63 isolated from Saccharomyces under denaturing conditions demonstrated reduced biological activity in a macrophage-killing assay compared to non-denatured rPA83 purified from Escherichia coli. Rabbits and non-human primates (NHP) immunized with rPA63 and later challenged with a lethal dose of B. anthracis spores were generally protected from infection. These results indicate that epitopes present in the 63-kDa from of PA can protect rabbits and non-human primates from a lethal spore challenge, and further suggest that a fully functional rPA63 is not required in order to provide these epitopes.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Evaluation the Efficacy of Anthrax Vaccine against Challenge with a Highly Virulent Strain of Bacillus anthracis Isolated from Soil in Sheep, Goats and Guinea Pigs in Iran

  Protection of animals immunized against Bacillus anthracis is usually demonstrated by challenging with an appropriate dose of a strain of Bacillus anthracis that is lethal to unvaccinated animals inoculated at the same time. In this study the protective efficacy in anthrax vaccine (34F2 sterne strain spore) was evaluated in sheep, goats and guinea pigs challenged with subcutaneous inoculation...

متن کامل

In Silico Prediction of B-Cell and T-Cell Epitopes of Protective Antigen of Bacillus anthracis in Development of Vaccines Against Anthrax

Protective antigen (PA), a subunit of anthrax toxin from Bacillus anthracis, is known as a dominant component in subunit vaccines in protection against anthrax. In order to avoid the side effects of live attenuated and killed organisms, the use of linear neutralizing epitopes of PA is recommended in order to design recombinant vaccines. The present study is aimed at determining the dominant epi...

متن کامل

Antibody titers of PEG-PLA block copolymer nanosphere containing chimeric recombinant protein of protective antigen and lethal factor of Bacillus anthracis

Introduction: To date, many vaccines have been developed for anthrax but not yet an ideal vaccine. In this study, chimeric protein containing domain 1 lethal factor and domain 4 protective antigens of Bacillus anthracis in copolymer nanocapsules were used to solve the problems caused by existing vaccines and to increase the efficiency of the proposed vaccine. Materials and Methods: In this expe...

متن کامل

Raxibacumab: potential role in the treatment of inhalational anthrax

Anthrax is a highly contagious and potentially fatal human disease caused by Bacillus anthracis, an aerobic, Gram-positive, spore-forming rod-shaped bacterium with worldwide distribution as a zoonotic infection in herbivore animals. Bioterrorist attacks with inhalational anthrax have prompted the development of more effective treatments. Antibodies against anthrax toxin have been shown to decre...

متن کامل

Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms.

A new anthrax vaccine under clinical investigation is based on recombinant Bacillus anthracis protective antigen (rPA). Here, we investigated microneedle-based cutaneous and nasal mucosal delivery of rPA in mice and rabbits. In mice, intradermal (id) delivery achieved up to 90% seroconversion after a single dose, compared with 20% after intramuscular (im) injection. Intranasal (inl) delivery of...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Vaccine

دوره 24 10  شماره 

صفحات  -

تاریخ انتشار 2006